​

Dianthus Therapeutics Stock (NASDAQ:DNTH)

ForecastRevenueOwnershipFinancialsChart
Dianthus Therapeutics by TradingView

Previous Close

$18.71

52W Range

$13.37 - $32.27

50D Avg

$20.76

200D Avg

$24.81

Market Cap

$617.14M

Avg Vol (3M)

$326.86K

Beta

1.63

Div Yield

-

DNTH Company Profile

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

78

IPO Date

Jun 21, 2018

Website

DNTH Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24
License$326.00K

Fiscal year ends in Dec 24 | Currency in USD

DNTH Financial Summary

Dec 24Dec 23Dec 22
Revenue$6.24M$2.83M$6.42M
Operating Income$-101.86M$-48.17M$-29.70M
Net Income$-84.97M$-43.55M$-28.48M
EBITDA$-101.86M$-48.17M$-29.56M
Basic EPS$-2.48$-8.45$-7.60
Diluted EPS$-2.48$-8.45$-7.60

Fiscal year ends in Dec 24 | Currency in USD